HOME >> BIOLOGY >> NEWS
A single sugar found responsible for an antibody's ability to treat inflammation

For years, researchers have struggled to understand how IVIG worked. It's ability to treat autoimmune diseases seemed to bean apparent contradiction.

Intravenous immunoglobulin (IVIG) is a complex mixture of IgG antibodies made from human plasma that contains the pooled antibodies from thousands of people, and is only FDA-approved to treat a few assorted conditions; nonetheless, practitioners have used it off-label with varied success in patients with lupus, arthritis and asthma, among other autoimmune disorders. In the body, the antibodies in plasma act as part of the immune response to identify and deactivate foreign invaders. When they begin attacking the body's own cells, the same protective immunoglobulins (known as IgG antibodies) can cause autoimmune disorders like lupus, arthritis and asthma. And yet, when IVIG is infused into people with those exact autoimmune conditions, it calms inflammation rather than causes it.

Jeffery Ravetch, Theresa and Eugene M. Lang Professor and head of Rockefeller's Laboratory of Molecular Genetics and Immunology, was struck by this inconsistency. "If IgG triggers autoimmune disease, how could it be pathogenic and therapeutic?" he asked. "We call it the IgG paradox." Six years ago he started an investigation into exactly how IVIG worked, and what he's discovered could one day lead to a whole new class of therapeutics. In a paper published today in the journal Science, Ravetch and his colleagues, Falk Nimmerjahn and Yoshi Kaneko explain what makes IVIG effective: A small fraction of the IgG antibodies in the IVIG solution carry a sugar called sialic acid that is required for its protective ability.

IgG antibodies bind to and activate specific immune cells, with different forms or "subclasses" binding to specific receptors (called Fc receptors) on the immune cell's surface. Antibody subclasses have different abilities to induce inflammation in the body by virtue of their selective ability to engage ei
'"/>

Contact: Kristine Kelly
kkelly@rockefeller.edu
212-327-7146
Rockefeller University
3-Aug-2006


Page: 1 2 3

Related biology news :

1. New research proves single origin of humans in Africa
2. 5 OHSU faculty members singled out for honors
3. TU Delft tracks the influence of a cancer inhibitor on a single DNA molecule
4. Caribbean frog populations started with single, ancient voyage on South American raft
5. Caribbean frogs started with a single, ancient voyage on a raft from South America
6. The social life of honeybees coordinated by a single gene
7. Penn researchers replace organ in adult mice using single-parent stem cells
8. Scripps research study reveals structural dynamics of single prion molecules
9. New nanotechnology able to examine single molecules, aiding in determining gene expression
10. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
11. Scientists discuss new frontiers in single-molecule research at American Chemical Society

Post Your Comments:
(Date:2/23/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announced today ... DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND SYSTEM. ... payment method. Payment accounts may be selected via voice ... if both the speech (the word associated with the ...
(Date:2/18/2015)... Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... speaking at the following conferences, and invited investors to participate ... Boston, MA Tuesday, March 3, 2015 ... Investors Conference, Orlando, FL Wednesday, March ... Live Webcasts To access the live webcasts for these events, ...
(Date:2/12/2015)... Feb. 12, 2015   MedNet Solutions , ... clinical study management systems, has recently bolstered its ... distinguishing iMedNet as the ... (CROs) and healthcare consultants.  Building on the Program,s ... referrals and numerous co-marketing opportunities), MedNet,s new and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
(Date:2/27/2015)... SUNNYVALE, Calif. , Feb. 27, 2015 /PRNewswire/ ... announced that longer-term toxicology studies for its newly ... arthritis, or RA, have been completed. The results ... the U.S. Food and Drug Administration. The feedback ... completion of the ongoing first-in-human study. Additional preclinical ...
(Date:2/27/2015)... 2015 The fully automated supercritical ... can sequentially analyze up to 48 samples utilizing ... detection of targets by mass spectrometry. , ... the measurement requirements of a wide range of ... delivery and search for disease biomarkers, additives in ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... WOODBRIDGE, N.J. , Feb. 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... a trade secrets lawsuit against Genewiz Inc. in excess ... obtained and utilized GenScript,s trade secrets, and that it ... court entered an order denying motions for judgment notwithstanding ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
Cached News: